

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 27, 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Nightstar Therapeutics plc

File No. 333-220289 - CF#35481

Nightstar Therapeutics plc submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form F-1 registration statement filed on August 31, 2017, as amended.

Based on representations by Nightstar Therapeutics plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.3	through August 29, 2027
Exhibit 10.4	through August 29, 2027
Exhibit 10.5	through August 29, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary